Statement of Principles concerning seborrhoeic dermatitis (Reasonable Hypothesis) (No. 43 of 2021)

The core concept is the reasonable hypothesis standard. Under section 120A of the VEA, a claim cannot succeed unless the material before the decision-maker raises a reasonable hypothesis connecting the disease with the circumstances of service. This instrument specifies what factors must exist for that hypothesis to be considered reasonable. It is not a strict proof of causation on the balance of probabilities; it is a lower threshold that a claimant must meet before the decision-maker goes on to consider whether the connection is more probable than not.

Seborrhoeic dermatitis is defined as an exfoliative, chronic dermatitis involving areas of increased sebaceous gland activity. The definition is specific: it does not cover every form of seborrhoeic dermatitis described in medical literature if it falls outside that description. The instrument notes that it characteristically affects the scalp, face, ears and flexural creases, providing a clinical reference point for decision-makers.

The instrument distinguishes between clinical onset and clinical worsening. Factors 1 through 8 apply to establishing a connection for the first occurrence of the condition. Factors 9 through 18 apply to aggravation where the condition was suffered or contracted before or during service but did not arise out of that service. This distinction matters because the time frame for when the factor must exist differs. For example, wearing a surgical mask or face covering (factor 17) applies only to clinical worsening, not to initial onset. The cumulative period of at least 20 hours in the seven days before worsening reflects a specific COVID-19 era consideration.

Relevant service is defined in the dictionary to mean operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. This excludes peacetime domestic service under the VEA that is not classified as operational, peacekeeping, hazardous or British nuclear test defence. It also excludes peacetime service under the MRCA unless it is warlike or non-warlike. This creates an important gap: a veteran whose seborrhoeic dermatitis develops during peacetime domestic service not captured by relevant service definitions may not be able to use this instrument.

The specified list of drugs is also a key concept. It includes biologic agents (therapeutic products derived from living organisms such as interferons, monoclonal antibodies, B-Raf inhibitors, epidermal growth factor receptor inhibitors, interleukins, MEK-inhibitors and tyrosine kinase inhibitors), capecitabine, and fluorouracil (including topical forms). These are drugs used for cancer or autoimmune disease treatment. The instrument requires that the drug be taken for at least seven days before clinical onset or worsening. There is also a separate catch-all factor (8 and 16) for any drug taken for at least seven days that is associated in the individual with the onset or worsening of seborrhoeic dermatitis, provided that improvement occurs within three months of discontinuation or tapering, or redevelopment on rechallenge. This catch-all factor is narrower because it requires an individualised temporal relationship and a drug trial.

Another critical concept is immobility. Factors 5 and 13 require being immobile for at least four weeks before clinical onset or worsening. Examples given include being in intensive care, having a spinal cord injury, or having facial paralysis (for facial seborrhoeic dermatitis). The note specifies what counts in certain contexts but leaves open other examples that might satisfy the definition.

The instrument also incorporates by reference other Statements of Principles. Under section 11, if a factor in section 9 refers to an injury or disease for which another Statement of Principles exists (such as HIV infection or Parkinson's disease), then the factors in that other SoP apply. This prevents having to re-prove causation for the factor condition itself.

The instrument directly affects veterans, members of the Peacekeeping Forces, and members of the Forces under the VEA, as well as members under the MRCA, who have or have had seborrhoeic dermatitis or who have died from it. Specifically, it affects those with relevant service as defined: operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. It does not affect members who have only peacetime domestic service not falling within those categories.

Claimants are the primary affected group. They must navigate the 18 factors and produce evidence linking one or more to their service. For veterans with HIV, Parkinson's disease, or who have received a solid organ transplant, the instrument provides a clear pathway if those conditions are service-related themselves (via other SoPs). For veterans who have taken biologic agents, capecitabine, or fluorouracil for cancer or autoimmune disease, and those drugs are service-related, the instrument again provides a pathway.

Veterans who are immobile due to a service-related condition such as a spinal cord injury or paralysis, or who are in intensive care as a result of service, also have a potential pathway through factors 5 and 13. The requirement of four weeks of immobility before clinical onset or worsening creates a temporal bar; a veteran who becomes immobile for a shorter period will not meet the factor.

The mask-wearing factor (17) affects veterans who wore surgical masks or face coverings intended to protect from human-to-human respiratory virus transmission for a cumulative period of at least 20 hours in the seven days before clinical worsening. This factor has no equivalent for clinical onset, meaning mask-wearing cannot establish a link for first occurrence. It only applies to worsening, and only where the worsening is related to service. This was likely added in response to increased mask use during the COVID-19 pandemic, but it imposes a specific evidence burden on the claimant to show both the duration and the purpose of the mask.

Health practitioners who provide care to veterans are indirectly affected. They may need to provide reports about whether their patient had seborrhoeic dermatitis, the timing of onset and worsening, and whether any of the listed factors were present and related to service. The instrument creates a demand for medical evidence, particularly around drug therapy timelines and immobility periods.

The Department of Veterans' Affairs, the Repatriation Commission, the Veterans' Review Board, and the Administrative Appeals Tribunal are directly affected as decision-makers. They must apply this instrument when assessing claims involving seborrhoeic dermatitis. They cannot accept a claim that does not meet the reasonable hypothesis standard as defined by these factors. This reduces their discretion but also creates administrative consistency.

The instrument does not impose duties on private individuals. It creates a right for eligible claimants to have their seborrhoeic dermatitis claim assessed under a specific set of factors. The key right is the right to have a reasonable hypothesis considered if at least one factor in section 9 is present and related to service. This is a threshold right: it does not guarantee compensation, but it opens the door to the decision-maker applying the balance of probabilities test.

The Repatriation Medical Authority has a duty to determine Statements of Principles under subsection 196B(2) of the VEA based on sound medical-scientific evidence. The Authority has performed that duty here, and its determination is binding. The Authority must also specify the factors that must exist, and it has done so in a list.

For claimants, there is a duty to produce evidence that a factor exists and is related to service. The instrument does not create an automatic presumption; the claimant bears the burden of proof to raise the reasonable hypothesis. The relationship to service requirement is set out in section 10: the factor must be related to the relevant service rendered by the person. For factors 9 to 18 (worsening factors), the subsection clarifies that they apply only to material contribution to or aggravation of seborrhoeic dermatitis where the person's seborrhoeic dermatitis was suffered or contracted before or during (but did not arise out of) the person's relevant service. This creates a distinction between initial onset and subsequent aggravation, and the claimant must identify which category applies.

The instrument also implicitly creates a right to have the application of other Statements of Principles considered. Section 11 provides that if a factor refers to an injury or disease covered by another SoP (e.g., HIV infection or Parkinson's disease), the factors in that other SoP apply. This prevents the decision-maker from requiring independent proof of the factor's link to service if that link has already been established through another SoP.

There is no right to challenge the instrument itself, as it is a legislative instrument made under statutory authority. However, affected persons can challenge how it is applied in their individual case, for example by arguing that a factor does exist and is related to service, or that the definition of seborrhoeic dermatitis is met.

This instrument does not contain any penalty provisions. It is not a criminal or regulatory prohibition but rather a rule for determining eligibility for compensation. Enforcement is indirect: if a claimant cannot satisfy the factors, their claim is denied. There is no sanction for failing to comply with the instrument's terms, only a loss of entitlement.

The real enforcement mechanism is the legal requirement that the Repatriation Commission, the Veterans' Review Board, and the Administrative Appeals Tribunal apply the instrument when deciding claims. If a decision-maker fails to apply the instrument correctly, the decision can be challenged through internal review and appeal to the Administrative Appeals Tribunal or the Federal Court. The instrument's legal effect is binding under section 120A of the VEA and section 338 of the MRCA.

Because the instrument repeals the 2013 SoP, any prior claims still pending must be assessed under this new instrument if they are still undecided after its commencement on 27 April 2021. The instrument does not provide transitional provisions, but the standard administrative law position is that the instrument in force at the time of decision applies, not the one at the time of the original claim. Claimants who had their claim decided under the 2013 SoP may have a different outcome if they seek review after the new instrument commenced.

The instrument does not create any duty on private parties to self-report or to take any action. Its enforcement is entirely through the administrative decision-making process. However, there is an indirect effect on healthcare providers if they are asked to provide evidence in support of a claim; failure to provide accurate evidence could have consequences under the general law (e.g., providing false information to a Commonwealth authority).

The instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986, which is the enabling statute. It interacts with section 120A of that Act, which provides that the reasonable hypothesis standard applies to claims for certain diseases, and that a Statement of Principles is determinative of whether a reasonable hypothesis exists. Similarly, it interacts with section 338 of the Military Rehabilitation and Compensation Act 2004.

The instrument interacts with other Statements of Principles through section 11. For example, if a claimant relies on factor 1 (HIV infection) to establish seborrhoeic dermatitis, HIV itself must be related to service. That connection will be determined by the Statement of Principles for HIV infection (if one exists). The instrument cross-references those SoPs as in force from time to time, meaning that amendments to the HIV SoP will automatically apply to seborrhoeic dermatitis claims using that factor.

The definition of seborrhoeic dermatitis interacts with the ICD-10-AM classification, Tenth Edition, effective 1 July 2017. This is a coding reference, but the instrument makes clear that the definition in subsection 7(2) prevails over the code. This prevents a situation where a code change would expand or narrow the condition covered.

The instrument also interacts with the general law of evidence and administrative law. The Repatriation Medical Authority's determination is a form of expert opinion that is binding on decision-makers. However, the instrument does not override the requirement that the decision-maker consider all the material before them; it only states that if the factors are not present, a reasonable hypothesis cannot be raised.

There is no direct interaction with state or territory workers' compensation laws, nor with private health insurance. The instrument is specific to the Commonwealth veterans' and military rehabilitation schemes. It does not affect criminal law, contract law, or tort law.

This instrument (No. 43 of 2021) repeals and replaces the previous Statement of Principles concerning seborrhoeic dermatitis No. 13 of 2013 (Federal Register of Legislation No. F2013L00405). The 2013 SoP was also made under subsection 196B(2) of the VEA. The current instrument commenced on 27 April 2021.

The source text does not disclose what specific changes were made compared to the 2013 version. However, the presence of factor 17 (wearing a surgical mask or face covering for a cumulative period of at least 20 hours in the seven days before clinical worsening) suggests a post-COVID-19 pandemic addition. The 2013 SoP would not have contained that factor. Similarly, the inclusion of biologic agents and specific drugs may have been updated.

The instrument notes that it applies to claims to which section 120A of the VEA or section 338 of the MRCA applies. This is standard for all SoPs. There is no separate amendment history recorded within the instrument itself beyond the repeal provision.

The instrument does not address transitional arrangements for claims made under the 2013 SoP that were still pending at commencement. In practice, the Veterans' Review Board and Administrative Appeals Tribunal apply the current instrument to claims still under consideration. This creates a risk for claimants who had a reasonable hypothesis under the old factors but not under the new ones.

The source text does not mention any litigation history. The instrument is a legislative determination, not a court decision. However, Statements of Principles are frequently litigated in the Administrative Appeals Tribunal and the Federal Court, particularly regarding whether the Repatriation Medical Authority has correctly applied the requirement for sound medical-scientific evidence, whether the factors are ultra vires, and whether the instrument applies to particular factual circumstances.

There is no publicly available litigation specifically about this instrument (No. 43 of 2021) mentioned in the source. Claimants who have been denied under this instrument can challenge the decision in the Administrative Appeals Tribunal, and the tribunal will apply the instrument. The Federal Court may review the instrument itself if there is a challenge to its validity, for example on the ground that the Authority did not have sufficient evidence for a factor.

Practitioners should be aware that the reasonable hypothesis standard is not a causation standard; it is a threshold standard. Courts have often clarified that the instrument does not require the claimant to prove the factor on the balance of probabilities; it only requires that the material points to a reasonable hypothesis consistent with the factors.

Several traps exist for claimants and practitioners in this instrument.

First, the definition of seborrhoeic dermatitis is specific: it must be an exfoliative, chronic dermatitis involving areas of increased sebaceous gland activity. A milder form of dandruff or dermatitis that does not involve increased sebaceous gland activity may not qualify. The ICD codes L21.0, L21.8, L21.9 are referenced but the definition prevails. A medical report must specifically address the definition.

Second, the relationship to service requirement under section 10 is strict. The factor must be related to the relevant service. It is not enough that the factor exists; it must be connected to the person's service. For example, a veteran may have HIV acquired through a blood transfusion given during peacetime service, but if that service is not relevant service as defined (e.g., not operational, not warlike), the factor may not be satisfied. The factor itself must be linked to relevant service through another SoP.

Third, the distinction between onset and worsening factors is critical. A claimant with pre-existing seborrhoeic dermatitis that worsened during service cannot use the onset factors (1-8). They must satisfy one of factors 9-18. Factor 18 (inability to obtain appropriate clinical management) applies to both onset and worsening based on its text, but note that it is listed only once and appears after the worsening factors, suggesting it applies to both but is physically located in the worsening section. The instrument's structure is unclear: factor 18 is not numbered as onset or worsening explicitly. It simply says "inability to obtain appropriate clinical management for seborrhoeic dermatitis." It appears under section 9 after factor 17, and section 9 is divided into onset (1-8) and worsening (9-18) based on the language of factors. But factor 18 does not specify onset or worsening. The better reading is that factor 18 applies to both onset and worsening, since it is a standalone factor that is not temporally qualified. This ambiguity is a trap.

Fourth, the immobility factors require being immobile for at least the four weeks before the clinical onset or worsening. It is not enough to have been immobile for four weeks in total; it must be the four weeks immediately preceding the onset or worsening. A veteran who is immobile for three weeks before onset then becomes mobile for a day will not meet the factor.

Fifth, the drug therapy factors (7 and 15) require taking a drug from the specified list for at least seven days before clinical onset or worsening. The seven days is calculated before onset, not total duration. A veteran who takes a biologic agent for seven days but the onset occurs on day six does not meet the factor. Similarly, the catch-all factors (8 and 16) require both a temporal association and either improvement within three months of discontinuation or redevelopment on rechallenge. A veteran who cannot demonstrate discontinuation or rechallenge due to ongoing treatment may not satisfy this factor.

Sixth, factor 17 (mask wearing) applies only to clinical worsening, not onset. It also requires that the mask or face covering was intended to provide protection from human-to-human respiratory virus transmission. A mask worn for other purposes, such as industrial dust or pollen, may not qualify. The cumulative 20 hours in the seven days before worsening is a specific evidentiary requirement. A veteran who wore a mask for 20 hours over the six-week period will not meet the factor.

Seventh, factor 18 is the broadest but most uncertain. It requires inability to obtain appropriate clinical management for seborrhoeic dermatitis. It does not specify what constitutes inability, or what clinical management is appropriate. A veteran who lives in a remote area with no dermatologist may argue inability, but the instrument provides no guidance on whether systemic barriers (cost, distance) qualify. This factor creates a risk of inconsistent decisions.

Eighth, the incorporation of other SoPs under section 11 means that the claimant must also satisfy the factors in those SoPs. If a claimant relies on HIV infection (factor 1), they must also satisfy the SoP for HIV. If the HIV SoP has been repealed or amended, the current version applies. The claimant cannot rely on the factor alone.

Ninth, the instrument does not cover all forms of dermatitis that might be linked to service. If a veteran has seborrhoeic dermatitis but the specific factor does not exist, the claim will fail even if medical opinion suggests a service connection through a novel pathway. The instrument is exhaustive for the reasonable hypothesis standard.

For claimants: the key is to identify which factor(s) may apply and gather evidence to support them. Medical records should document the diagnosis of seborrhoeic dermatitis in precise terms consistent with the definition. Clinical notes should indicate the date of onset and any worsening episodes. For immobility factors, records of intensive care stays, spinal cord injuries, or paralysis should be obtained. The four-week period must be clearly shown.

For drug therapy factors, claimants should obtain prescription records, hospital charts, or patient medication lists that show the drug was taken for at least seven days before onset or worsening. If the drug is a biologic agent, capecitabine, or fluorouracil, the records should confirm that it was used for cancer or autoimmune disease treatment. For the catch-all drug factors, the treating doctor should provide evidence of the temporal association, including documentation of improvement within three months of discontinuation or tapering, or redevelopment on rechallenge.

For the mask-wearing factor, claimants should collect evidence of mask use, such as employer records, work schedules, or personal notes, and show that the mask was worn for at least 20 cumulative hours in the seven days before worsening. The purpose of the mask must be documented as protection from respiratory virus transmission, not just general mask use.

For factor 18 (inability to obtain appropriate clinical management), claimants should document attempts to access treatment, such as letters from doctors, referrals, wait times, or geographic distance from services. The decision-maker will need evidence that appropriate management was not reasonably available.

Practitioners should carefully map the chronological sequence of the factor relative to onset or worsening. They should also verify that the factor is related to relevant service. If the factor itself is a condition like HIV, Parkinson's disease, or immobility, the practitioner must also establish that condition's connection to service through its own SoP.

For decision-makers: the instrument must be applied strictly. The definitions in the schedule are controlling. The term "seborrhoeic dermatitis" is defined by clause 7(2), not by common medical parlance. The ICD code is a guide only. The factor must exist as a minimum; even if other medical evidence suggests a link, if none of the listed factors exist, the reasonable hypothesis is not raised.

When applying factor 18, decision-makers must decide whether the claimant had an inability to obtain appropriate clinical management. This is a factual determination. The examples in the notes under other factors are not exhaustive but provide guidance. The decision-maker should consider whether the claimant had access to a general practitioner, a dermatologist, or other qualified health professional, and whether the claimant could afford or physically access such care. The term "appropriate clinical management" is not defined, but it presumably means treatment that is in accordance with accepted medical standards for seborrhoeic dermatitis.

Practitioners should also be aware of the potential for multiple factors to apply. The instrument requires at least one factor, but more than one may strengthen the hypothesis. However, each factor must be independently linked to service.

Compliance costs primarily fall on claimants in terms of gathering medical evidence and legal advice. There is no compliance burden on private businesses or the general public. The instrument's specificity reduces administrative costs for decision-makers by providing a checklist approach, but it also increases the risk that a meritorious claim might fail due to lack of evidence for a very specific factor (e.g., confirming mask purpose).